<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Minerva Neurosciences, Inc — News on 6ix</title>
<link>https://6ix.com/company/minerva-neurosciences-inc</link>
<description>Latest news and press releases for Minerva Neurosciences, Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/minerva-neurosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a17c78dffbe2df109510.webp</url>
<title>Minerva Neurosciences, Inc</title>
<link>https://6ix.com/company/minerva-neurosciences-inc</link>
</image>
<item>
<title>Minerva Announces Leadership Transition</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-announces-leadership-transition</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-announces-leadership-transition</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Jim O’Connor joins as Chief Business Officer and General Counsel BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:</description>
</item>
<item>
<title>Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia-4</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia-4</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need</description>
</item>
<item>
<title>Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-presents-data-from-its-open-label-safety-trial-evaluating-roluperidone-co-administered-with-olanzapine-at-sirs-2026</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-presents-data-from-its-open-label-safety-trial-evaluating-roluperidone-co-administered-with-olanzapine-at-sirs-2026</guid>
<pubDate>Wed, 25 Mar 2026 20:05:00 GMT</pubDate>
<description>Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of</description>
</item>
<item>
<title>Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-to-participate-in-the-stifel-2026-virtual-cns-forum-9</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-to-participate-in-the-stifel-2026-virtual-cns-forum-9</guid>
<pubDate>Thu, 12 Mar 2026 11:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026. The Stifel 2026 Virtual CNS ForumFormat:Company presentationDay/Time:Wednesday, March 18 at 8.30 AM ETW</description>
</item>
<item>
<title>Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-business-updates</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H</description>
</item>
<item>
<title>Minerva Neurosciences to Participate in The Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-to-participate-in-the-citizens-life-sciences-conference-12</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-to-participate-in-the-citizens-life-sciences-conference-12</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-host-virtual-kol-120000701</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-host-virtual-kol-120000701</guid>
<pubDate>Mon, 26 Jan 2026 12:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, Univ</description>
</item>
<item>
<title>Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-appoints-dr-inderjit-133000793</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-appoints-dr-inderjit-133000793</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successf</description>
</item>
<item>
<title>Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-third-quarter-123000756</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-third-quarter-123000756</guid>
<pubDate>Wed, 05 Nov 2025 12:30:00 GMT</pubDate>
<description>BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The f</description>
</item>
<item>
<title>Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-announces-financing-200-120000875</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-announces-financing-200-120000875</guid>
<pubDate>Tue, 21 Oct 2025 12:00:00 GMT</pubDate>
<description>Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 million proceeds may be received in connection with cash exercise of Tranche B warrants contingent upon achievement of milestone event. With the proceeds of the financing and alignment with the FDA, Minerva is expected to be sufficiently funded through th</description>
</item>
<item>
<title>Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Prepara...</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-announces-financing-of-up-to-dollar200-million-to-advance-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia-through-a-phase-3-confirmatory-trial-and-resubmission-of-its-new-drug-application-and-prepara</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-announces-financing-of-up-to-dollar200-million-to-advance-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia-through-a-phase-3-confirmatory-trial-and-resubmission-of-its-new-drug-application-and-prepara</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia</description>
</item>
<item>
<title>Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-provides-business-updates-203500100</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-provides-business-updates-203500100</guid>
<pubDate>Thu, 14 Aug 2025 20:35:00 GMT</pubDate>
<description>FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with th</description>
</item>
<item>
<title>Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-first-quarter-113000829</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-first-quarter-113000829</guid>
<pubDate>Tue, 13 May 2025 11:30:00 GMT</pubDate>
<description>BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025. Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue t</description>
</item>
<item>
<title>Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-fourth-quarter-120000170</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-fourth-quarter-120000170</guid>
<pubDate>Tue, 25 Feb 2025 12:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024. Corporate Update As previously disclosed in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New</description>
</item>
<item>
<title>Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-third-quarter-2024-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-third-quarter-2024-financial-results-and-business-updates</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-second-quarter-2024-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-second-quarter-2024-financial-results-and-business-updates</guid>
<pubDate>Tue, 06 Aug 2024 04:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-first-quarter-2024-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-first-quarter-2024-financial-results-and-business-updates</guid>
<pubDate>Wed, 01 May 2024 04:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia</guid>
<pubDate>Tue, 27 Feb 2024 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-business-updates</guid>
<pubDate>Thu, 22 Feb 2024 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates</title>
<link>https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-2023-third-quarter-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/minerva-neurosciences-inc/news/minerva-neurosciences-reports-2023-third-quarter-financial-results-and-business-updates</guid>
<pubDate>Tue, 07 Nov 2023 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the</description>
</item>
</channel>
</rss>